Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.

We’re excited to share Alexza’s new corporate identity. It’s a brand that expresses our evolution and brings us closer to Ferrer, our parent company since 2016. We’re moving forward and, at the same time, staying true to our objective of offering high-quality pharmaceutical products for the acute treatment of disease, in order to make a positive impact in society. We are Ferrer, Ferrer for good.

Kriya Therapeutics, Inc. is a biopharmaceutical company developing gene therapies for diseases affecting millions of people around the world. With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $450 million to advance a broad pipeline of gene therapies for ophthalmology, neurology, and metabolic diseases.

Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, tarcocimab tedromer, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including wet age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development. KSI-501 is our dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases. We are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. WORKING AT KODIAK We foster a culture of curiosity, creativity, compassion and courage. Our collective goal is to make a difference in the world. We do that as a team driven by the shared desire to tackle some of the world’s biggest challenges. If this sounds exciting, we want to hear from you! Kodiak supports a vibrant and active lifestyle, striving to provide an optimal work-life balance. We are located in Palo Alto, in the heart of the world-class biotech hub of Silicon Valley, and within walking distance to California Avenue’s shops, restaurants and public transportation.

Fulcrum is a pioneer in making low-carbon, low-cost, transportation fuels from one of our nation’s most abundant resources – household garbage. As a company, we are committed to improving the quality of life in our communities – and that starts with solving a fundamental problem in America: too much garbage. Utilizing trash as a feedstock, Fulcrum is diverting large volumes of waste from local landfills and reducing greenhouse gas emissions by more than 100% compared to traditional petroleum fuel. Fulcrum is making a difference today, and we are leading the way to a clean and sustainable future for America.

K2 Pure Solutions helps provide an answer to eliminating the need to transport chlorine for water purification and disinfection, as well as other industries, by deploying and funding a North American wide network of state-of-the-art facilities utilizing inherently safe technology. For more information, please visit: www.k2pure.com

G.S. COSMECEUTICAL USA, Inc., a skin care, body care and hair care custom contract manufacturer and formulation lab, is FDA registered and cGMP-compliant personal care products manufacturer located in Livermore, California. Since 1998 GSC has built its reputation on developing distinctive, luxurious and highly effective OTC, cosmeceutical, cosmetic, natural/organic and physician-dispensed products using cutting-edge raw materials sourced from around the world. We custom contract manufacture formulations used from head-to-toe by people of all ages, ethnicities and skin types, sold across all channels of distribution both nationally and internationally. CEO and Founder Gogi Sangha holds a Masters of Philosophy (M.Phil.) in organic chemistry and has 30+ years'​ R&D experience in the pharmaceutical, OTC and personal care industries. Sangha developed the NDA for Retin-A® Micro prior to its patent by Johnson & Johnson and is an expert in Microsponge® delivery system technology. Our business partners include some of the most successful skincare and consumer products corporations in the world, as well as mid-sized and niche companies. We also establish lines for dermatologists, aesthetic surgeons and estheticians and help put young, entrepreneurial start-ups on the map.

Fosun Pharma USA Inc. was founded in 2017 and continually works to enhance our existing portfolio of specialty pharmaceutical injectables, COVID19 related products and to build our pipeline with both innovative and generic pharmaceutical drugs. With strategic manufacturing partnerships around the world, Fosun Pharma USA Inc. delivers high-quality products that comply with international standards.

Sun Deep Cosmetics is a prestigious and progressive private label manufacturer of natural and organic personal care cosmetics, toiletries and OTC products. Sun Deep offers custom formulated products for retailers, distributors, marketers, and entrepreneurs. Sun Deep cosmetics began making products in the natural and organic markets many years ago long before the term “organic” became fashionable. We constantly strive to raise the bar with new technologies that allow us to make performance products without the use of conventional synthetic ingredients. The goal of Sun Deep is to provide our customers with outstanding quality and service from product conception to completion, using state of the art technologies and processing methods. Sun Deep’s seasoned product development team has developed hundreds of successful products for mass market and the exclusive health food store market. Our knowledge of natural and organic formulations and markets will ensure the success of your products and will give you the competitive edge to tackle the health food industry and their ever-stringent standards. Only our quality product matches Sun Deep’s flexibility in production.

Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.

Henlius USA Inc., located in Milpitas, CA, focuses on developing and delivering high-quality, innovative, and affordable medicine to patients worldwide to treat a range of chronic and life-threatening diseases with a focus in oncology and autoimmune diseases. Henlius USA Inc., is affiliated with Shanghai Henlius Biotech, a global biopharmaceutical company established in 2010. Henlius’ diverse pipeline of over 20 innovative monoclonal antibodies (mAb) includes 汉利康® (HLX01, rituximab injection, the first commercially launched biosimilar in China), 汉曲优® (HLX02, trastuzumab injection, Zercepac® in the EU, first Chinese mAb biosimilar approved in both EU and China), 2 products under NDA review, and over 20 clinical studies for 10 products and 8 combination therapies worldwide. Our goal at Henlius USA Inc., is to accelerate the discovery and development of innovative biologics (such as monoclonal and bispecific antibody) through technical and operational excellence and to build a leading immuno-oncology franchise with a diverse and distinguished product portfolio. We aim to be a globally trusted biotech company dedicated to bringing affordable, innovative treatment to patients with unmet medical needs worldwide. Henlius: http://www.henlius.com